- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Bicara Therapeutics stock maintains Buy rating at BTIG on clinical progress | 1 | Investing.com | ||
| Mo | Bicara legt optimale Dosis für zulassungsrelevante Studie zu Kopf-Hals-Krebs fest | 1 | Investing.com Deutsch | ||
| Mo | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.01. | BTIG nimmt Coverage für Bicara Therapeutics mit "Buy"-Rating auf | 2 | Investing.com Deutsch | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | BTIG initiates coverage on Bicara Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 17.12.25 | Mizuho initiates Bicara Therapeutics stock coverage with Neutral rating | 1 | Investing.com | ||
| 17.12.25 | Mizuho startet Coverage für Bicara Therapeutics mit "Neutral"-Einstufung | - | Investing.com Deutsch | ||
| 08.12.25 | Bicara stock maintains Buy rating at Stifel after ESMO-Asia data | 2 | Investing.com | ||
| 08.12.25 | Bicara: Stifel bestätigt Kaufempfehlung nach ESMO-Asia-Daten | 1 | Investing.com Deutsch | ||
| 08.12.25 | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.12.25 | Bicara Therapeutics Inc.: Bicara Therapeutics' Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026 | 117 | GlobeNewswire (Europe) | Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study... ► Artikel lesen | |
| 01.12.25 | Bicara: Krebswirkstoff Ficerafusp Alfa zeigt auch bei niedrigerer Dosis konstante Ansprechraten | 1 | Investing.com Deutsch | ||
| 01.12.25 | Bicara's ficerafusp alfa shows consistent response rates at lower dose | 1 | Investing.com | ||
| 10.11.25 | Bicara Therapeutics GAAP EPS of -$0.67 | 3 | Seeking Alpha | ||
| 10.11.25 | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 152 | GlobeNewswire (Europe) | Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp... ► Artikel lesen | |
| 10.11.25 | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.10.25 | Bicara stock jumps after FDA grants breakthrough therapy status | 2 | Investing.com | ||
| 13.10.25 | Why Bicara Therapeutics Is Rising In Pre-market? | - | RTTNews | ||
| 13.10.25 | FDA grants breakthrough therapy status to Bicara's cancer drug | 3 | Investing.com | ||
| 13.10.25 | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC | 258 | GlobeNewswire (Europe) | BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 317,25 | +6,55 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy | BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,51 | -0,12 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 71,14 | -3,41 % | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | ||
| STRUCTURE THERAPEUTICS | 88,64 | +4,26 % | Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why | ||
| QIAGEN | 40,990 | +0,42 % | QIAGEN - hält was es verspricht | Das Unternehmen aus Hilden hat seine Prognosen im abgelaufenen Geschäftsjahr erreicht. Nun geht es optimistisch in das neue Jahr, in dem es sich auf die Förderung der Produktvermarktung, regulatorische... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,310 | -1,09 % | ADMA Biologics, Inc. (ADMA): A Bull Case Theory | ||
| BEAM THERAPEUTICS | 31,220 | -2,59 % | AKTIONÄR-Tipp Beam Therapeutics wie entfesselt: Die Hintergründe! | Innerhalb der Biotech-Branche zählt der Bereich Gen-Schere zu den absoluten Top-Trends. Neben der wohlbekanntesten seiner Klasse, CRISPR/Cas9, entwickeln sich auch andere Ansätze weiter. Dazu zählt... ► Artikel lesen | |
| ERASCA | 9,625 | +0,68 % | Erasca, Inc.: Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones | Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for... ► Artikel lesen | |
| CG ONCOLOGY | 54,73 | +3,13 % | CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why | ||
| JANUX THERAPEUTICS | 13,760 | +0,29 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| IMMUNOME | 22,410 | -1,93 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| TANGO THERAPEUTICS | 13,010 | +11,29 % | Tango Therapeutics stock maintains Buy rating at Stifel on encouraging early data | ||
| AMYLYX PHARMACEUTICALS | 14,300 | +5,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 10,160 | -3,24 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,350 | -3,67 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 | Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with... ► Artikel lesen |
BICARA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,750 Euro und damit +0,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.